Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Other solid neoplasm 1

Conditions

Advanced Solid Tumor 130Advanced Solid Tumors 122Solid Tumor 101Mesothelioma, Malignant 48Solid Tumors 43Mesothelioma 42Hematopoietic and Lymphatic System Neoplasm 30Solid Tumor, Adult 27Retinoblastoma 20Pancreatic Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 13Lung Neoplasms 13Neoplasms 11Advanced Malignant Solid Tumor 11Advanced or Metastatic Solid Tumors 10Solid Tumors, Adult 9Sarcoma 9Hematopoietic and Lymphoid System Neoplasm 9Advanced Malignant Solid Tumors 9Stomach Neoplasms 8Solid Tumor Malignancies 8Neoplasm Metastasis 8Melanoma 8Malignant Solid Tumors 8Malignant Solid Neoplasm 8Locally Advanced or Metastatic Solid Tumors 8Kidney Neoplasms 8Colorectal Neoplasms 8Advanced/Metastatic Solid Tumors 8

Interventions

1-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Platinum-resistant Recurrent Ovarian Cancer × Other solid neoplasm × Clear all
NCT06687070 2025-02-26

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Ascentage Pharma Group Inc.

Phase 1 Recruiting
50 enrolled
GynecologicOther solid neoplasm

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡